Check Before You Invest : Eris Lifesciences Ltd

Q: Which industry/sub-sector does Eris Lifesciences Ltd belong to?

Eris Lifesciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q: Is Eris Lifesciences Ltd a good quality company?

Eris Lifesciences Ltd is a good quality company, based on a consistently good multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Eris Lifesciences Ltd undervalued or overvalued?

Eris Lifesciences Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 31.29, Historic Median: 30.73. Price to Book, Current: 4.97, Historic Median: 5.28. Price to Sales, Current: 6.22, Historic Median: 6.83. EV to EBITDA, Current: 19.18, Historic Median: 20.48

Q: Is Eris Lifesciences Ltd a good buy now?

Eris Lifesciences Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Eris Lifesciences Ltd?

Eris Lifesciences Ltd revenue growth is 44% for FY-2025, which is above its 5-year CAGR of 21.92%, indicating faster growth.

Q: Gross Profit margin of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 27.1% for FY-2025, which is below its 5-year median of 29.6%, indicating decreasing margins.

Q: Operating Profit Margin of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 35.18% for FY-2025, which is in line with its 5-year median of 35.18% indicating stable margins.

Q: Net Profit Margin of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Net Profit Margin is 12.95% for FY-2025, is below its 5-year median of 22.2%, indicating decreasing margins. Profitability Metrics. Gross Profit Margin (%), Current: 27.1, Historic Median: 29.6. Operating Profit Margin (%), Current: 35.18, Historic Median: 35.18. Net Profit Margin (%), Current: 12.95, Historic Median: 22.2

Q: Return on Asset of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Return on Asset is 5.48%, which is below its 5-year historical median of 13.4%, indicating deteriorated asset utilization efficiency.

Q: Return on capital employed (ROCE) of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Return on capital employed is 13.59% for FY-2025, which is below its 5-year historical median of 17.3%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 13.5%, indicating value creation.

Check Before You Invest : Eris Lifesciences Ltd

Snapshot

Q.1 Which industry/sub-sector does Eris Lifesciences Ltd belong to?

Eris Lifesciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Eris Lifesciences Ltd a good quality company?

Eris Lifesciences Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Eris Lifesciences Ltd undervalued or overvalued?

Eris Lifesciences Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	31.29	30.73
Price to Book	4.97	5.28
Price to Sales	6.22	6.83
EV to EBITDA	19.18	20.48

Q.4 Is Eris Lifesciences Ltd a good buy now?

Eris Lifesciences Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Eris Lifesciences Ltd?

Eris Lifesciences Ltd revenue growth is 44% for FY-2025, which is above its 5-year CAGR of 21.92%, indicating faster growth.

Q.2 Gross Profit margin of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 27.1% for FY-2025, which is below its 5-year median of 29.6%, indicating decreasing margins.

Q.3 Operating Profit Margin of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 35.18% for FY-2025, which is in line with its 5-year median of 35.18% indicating stable margins.

Q.4 Net Profit Margin of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Net Profit Margin is 12.95% for FY-2025, is below its 5-year median of 22.2%, indicating decreasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	27.1	29.6
Operating Profit Margin (%)	35.18	35.18
Net Profit Margin (%)	12.95	22.2

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Return on Asset is 5.48%, which is below its 5-year historical median of 13.4%, indicating deteriorated asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Return on capital employed is 13.59% for FY-2025, which is below its 5-year historical median of 17.3%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 13.5%, indicating value creation.

Q.7 Return on Equity (ROE) of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Return on equity is 13.81% for FY-2025, which is below its 5-year historical median of 18.25%, indicating the business is making worse use of its shareholders capital.

Q.8 Cash conversion cycle of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Cash conversion cycle is 34 days, above its 5-year historical median of 29 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	0.43	0.63
ROE (%)	13.81	18.25
ROCE (%)	13.59	17.3
Cash Conversion Cycle	34 days	29 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Debt-to-Equity ratio is 0.85, which is above the industry average of 0.14, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Eris Lifesciences Ltd?

Eris Lifesciences Ltd Debt to cash flow from operations is 2.27, which is at a moderate level.

Ownership & governance

D: Promoter shareholding and pledge status of Eris Lifesciences Ltd?

Q.1 Promoter shareholding and pledge status of Eris Lifesciences Ltd?

Promoters hold 54.14% of the Eris Lifesciences Ltd, with 16.85% of their stake pledged, indicating high pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Eris Lifesciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Eris Lifesciences Ltd vs industry peers?

Eris Lifesciences Ltd revenue CAGR is 21.92%, compared to the industry median CAGR of 5.34%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	44	5.3
Gross Profit Growth (%)	30.9	11.8
Operating Profit Growth (%)	50.7	10.8
Net Profit Growth (%)	-5.5	12.1

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	0.43	0.78
ROE (%)	13.81	8.58
ROCE (%)	13.59	10.85
Cash Conversion Cycle (days)	34.08	76

Valuation & price assessment

Q.1 Stock return of Eris Lifesciences Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 12.87% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	-	12.9%	22.5%	-22%

Q.2 Valuation ratios of Eris Lifesciences Ltd vs historical?

The current P/E ratio of 31.29 is in line with than its historical median of 30.73, indicating that the stock is trading near its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	31.29	30.73	31.09
Price to Book	4.97	5.28	2.85
Price to Sales	6.22	6.83	2.82
EV to EBITDA	19.18	20.48	15.99

Check more companies

3. Wockhardt

7. Neuland Laboratories

8. Pfizer

9. Granules India

10. Astrazeneca Pharma

Check trending companies

1. Angel One Ltd.

2. Welspun Corp Ltd.

3. Acutaas Chemicals Ltd.

4. The Indian Hotels Company Ltd.

5. Samvardhana Motherson International Ltd.

Check Before You Invest : Eris Lifesciences Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.